ArticleBrain communications2023

Responder analyses for anti-amyloid immunotherapies for Alzheimer's disease: a paradigm shift by regulatory authorities is urgently needed.

Simone Salemme et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.